Look at Full Prescribing Information OPDIVO® (nivolumab) is indicated to the treatment of adult patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed right after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or immediately after 3 or even more lines of systemic therapy that featu